KC Herold, SE Gitelman, U Masharani, W … - Diabetes, 2005 - Am Diabetes Assoc Despite advances in understanding autoimmune diabetes in animal models, there
has been little progress in altering the natural course of the human disease,
which involves progression to insulin deficiency. Studies with ... Cited by 166 - Related articles - All 4 versions
- ►shouxi.net … E Vandemeulebroucke, AG Ziegler, C Mathieu … - The New England journal of medicine, 2005 - nejm.highwire.org Bart Keymeulen, MD, Ph.D., Evy Vandemeulebroucke, MD, Anette G. Ziegler, MD,
Ph.D., Chantal Mathieu, MD, Ph.D., Leonard Kaufman, Ph.D., Geoff Hale, Ph.D.,
Frans Gorus, MD, Ph.D., Michel Goldman, MD, Ph.D., Markus Walter, MD, ... Cited by 312 - Related articles - All 13 versions
- ►shouxi.net KC Herold, SE Gitelman, U Masharani, W … - Diabetes, 2005 - Am Diabetes Assoc Page 1. A Single Course of Anti-CD3 Monoclonal Antibody hOKT3 1(Ala-Ala)
Results in Improvement in C-Peptide Responses and Clinical ... Cited by 13 - Related articles - All 3 versions
- ►nih.gov D Bresson, L Togher, E Rodrigo, Y Chen, JA … - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig Safe induction of autoantigen-specific long-term tolerance is the “holy
grail” for the treatment of autoimmune diseases. In animal models of type 1
diabetes, oral or in immunization with islet antigens induces Tregs that ... Cited by 91 - Related articles - BL Direct - All 12 versions
- ►columbia.edu [PDF] KC Herold, W Hagopian, JA Auger, E Poumian- … - New England Journal of Medicine, 2002 - content.nejm.org Results Treatment with the monoclonal antibody maintained or improved insulin
production after one year in 9 of the 12 patients in the treatment group,
whereas only 2 of the 12 controls had a sustained response (P=0.01). The ... Cited by 472 - Related articles - BL Direct - All 11 versions
M Belghith, JA Bluestone, S Barriot, J Mégret … - Nature medicine, 2003 - nature.com CD3-specific antibodies have the unique capacity to restore self-tolerance in
established autoimmunity. They induce long-term remission of overt diabetes in
nonobese diabetic (NOD) mice and in human type I diabetes. The underlying ... Cited by 335 - Related articles - BL Direct - All 3 versions
- ►nih.gov KC Herold, JB Burton, F Francois, E Poumian- … - Journal of clinical investigation, 2003 - Am Soc Clin Investig Dimeric Fc receptor (FcR) nonbinding anti-CD3 antibodies have been developed to
minimize toxicities associated with classical anti-CD3 monoclonal antibodies
(eg, OKT3). Studies with murine analogs of non-FcR–binding antibodies ... Cited by 120 - Related articles - BL Direct - All 8 versions
- ►nih.gov [PDF] L Chatenoud, E Thervet, J Primo, JF Bach - Proc Natl Acad Sci USA, 1994 - National Acad Sciences Institut National de la Sant6 et de la Recherche M6dicale U 25, H6pital Necker,
161 Rue de Sevres, 75015 Paris, France Communicated by N. Le Douarin, August 23,
1993 ... ABSTRACT Anti-CD3 monoclonal antibodies suppress immune ... Cited by 294 - Related articles - BL Direct - All 10 versions
- ►nih.gov B Bisikirska, J Colgan, J Luban, JA Bluestone … - Journal of Clinical Investigation, 2005 - Am Soc Clin Investig Modified anti-CD3 mAbs are emerging as a possible means of inducing immunologic
tolerance in settings including transplantation and autoimmunity such as in type
1 diabetes. In a trial of a modified anti-CD3 mAb [hOKT3γ1(Ala-Ala)] in ... Cited by 137 - Related articles - BL Direct - All 12 versions
L Chatenoud, J Primo, JF Bach - The Journal of Immunology, 1997 - Am Assoc Immnol Page 1. CD3 Antibody-Induced Dominant Self Tolerance in Overtly Diabetic NOD Mice'
Lucienne Chatenoud,2 Jacqueline Primo, and Jean-Frangois Bach ... Cited by 199 - Related articles - BL Direct - All 4 versions
